This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Novartis Pharmaceuticals Corporation.
Reference
Vogelzang NJ, et al. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis. Advances in Therapy : 26 Oct 2017. Available from: URL: http://doi.org/10.1007/s12325-017-0628-2
Rights and permissions
About this article
Cite this article
Pazopanib in elderly with aRCC: better outcomes, lower cost. PharmacoEcon Outcomes News 791, 23 (2017). https://doi.org/10.1007/s40274-017-4507-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4507-5